Deutsche Bank AG Invests $2.37 Million in Alumis Inc. $ALMS

Deutsche Bank AG bought a new position in shares of Alumis Inc. (NASDAQ:ALMS) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 84,113 shares of the company’s stock, valued at approximately $2,367,000.

Several other hedge funds have also added to or reduced their stakes in the business. Ieq Capital LLC boosted its position in Alumis by 4.1% during the fourth quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock worth $170,000 after purchasing an additional 690 shares during the period. Strs Ohio increased its holdings in shares of Alumis by 300.0% in the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after purchasing an additional 1,500 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Alumis by 12.4% in the fourth quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock valued at $143,000 after purchasing an additional 1,618 shares during the period. KBC Group NV acquired a new stake in shares of Alumis during the 1st quarter worth about $42,000. Finally, State of Wyoming acquired a new stake in shares of Alumis during the 1st quarter worth about $57,000.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ALMS shares. Citigroup reiterated a “neutral” rating on shares of Alumis in a research note on Monday, August 17th. HC Wainwright restated a “neutral” rating and set a $25.00 price objective on shares of Alumis in a research report on Friday, August 14th. Morgan Stanley restated an “overweight” rating and set a $39.00 price objective on shares of Alumis in a report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. Finally, Wells Fargo & Company increased their target price on Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.30.

Alumis Trading Down 1.7%

NASDAQ ALMS opened at $23.21 on Friday. Alumis Inc. has a 1-year low of $3.76 and a 1-year high of $31.35. The company has a 50 day moving average of $26.57 and a 200-day moving average of $25.11. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -6.01 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%.The company had revenue of $1.66 million for the quarter, compared to analyst estimates of $3.65 million. On average, equities research analysts forecast that Alumis Inc. will post -2.95 earnings per share for the current year.

Insider Activity

In other news, insider Roy C. Hardiman sold 2,692 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $70,988.04. Following the completion of the sale, the insider directly owned 207,746 shares in the company, valued at approximately $5,478,262.02. This represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Sanam Pangali sold 1,364 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $35,968.68. Following the sale, the insider directly owned 9,747 shares in the company, valued at approximately $257,028.39. This trade represents a 12.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 19,953 shares of company stock worth $534,311. 33.70% of the stock is owned by insiders.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.